Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Studyopen access
- Authors
- Baek, Yae Jee; Lee, Youn-Jung; Park, So Ra; Kim, Kyoo Hyun; Beom, Seung-Hoon; Lee, Choong-kun; Shin, Sang Joon; Rha, Sun Young; Kim, Sinyoung; Lee, Kyoung Hwa; Kim, Jung Ho; Jeong, Su Jin; Ku, Nam Su; Choi, Jun Yong; Yeom, Joon-Sup; Jung, Minkyu; Ahn, Jin Young
- Issue Date
- Jul-2023
- Publisher
- KOREAN CANCER ASSOCIATION
- Keywords
- Immunogenicity; Reactogenicity; COVID-19 vaccine; Solid cancer; Chemotherapy
- Citation
- CANCER RESEARCH AND TREATMENT, v.55, no.3, pp 746 - 757
- Pages
- 12
- Journal Title
- CANCER RESEARCH AND TREATMENT
- Volume
- 55
- Number
- 3
- Start Page
- 746
- End Page
- 757
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26544
- DOI
- 10.4143/crt.2022.1541
- ISSN
- 1598-2998
2005-9256
- Abstract
- Purpose We aimed to assess the humoral response to and reactogenicity of coronavirus disease 2019 (COVID-19) vaccination according to the vaccine type and to analyze factors associated with immunogenicity in actively treated solid cancer patients (CPs). Materials and Methods Prospective cohorts of CPs, undergoing anticancer treatment, and healthcare workers (HCWs) were established. The participants had no history of previous COVID-19 and received either mRNA-based or adenovirus vector-based (AdV) vaccines as the primary series. Blood samples were collected before the first vaccination and after 2 weeks for each dose vaccination. Spike-specific binding antibodies (bAbs) in all participants and neutralizing antibodies (nAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wild-type, Delta, and Omicron variants in CPs were analyzed and presented as the geometric mean titer.Results Age-matched 20 HCWs and 118 CPs were included in the analysis. The bAb seroconversion rate and antibody concentrations after the first vaccination were significantly lower in CPs than in HCWs. After the third vaccination, antibody levels in CPs with a primary series of AdV were comparable to those in HCWs, but nAb titers against the Omicron variant did not quantitatively increase in CPs with AdV vaccine as the primary series. The incidence and severity of adverse reactions post-vaccination were similar between CPs and HCWs. Conclusion CPs displayed delayed humoral immune response after SARS-CoV-2 vaccination. The booster dose elicited comparable bAb concentrations between CPs and HCWs, regardless of the primary vaccine type. Neutralization against the Omicron variant was not robustly elicited following the booster dose in some CPs, implying the need for additional interventions to protect them from COVID-19.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26544)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.